Lipocine (NASDAQ:LPCN) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Lipocine (NASDAQ:LPCN) in a research report released on Wednesday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Lipocine Stock Up 0.3 %

Shares of NASDAQ:LPCN opened at $3.19 on Wednesday. The firm has a market capitalization of $17.07 million, a PE ratio of -4.20 and a beta of 1.51. The company has a 50-day moving average price of $3.22 and a two-hundred day moving average price of $4.28. Lipocine has a twelve month low of $2.75 and a twelve month high of $11.79.

Institutional Investors Weigh In On Lipocine

An institutional investor recently raised its position in Lipocine stock. Geode Capital Management LLC lifted its stake in Lipocine Inc. (NASDAQ:LPCN) by 6.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 57,464 shares of the specialty pharmaceutical company’s stock after acquiring an additional 3,248 shares during the period. Geode Capital Management LLC owned approximately 1.07% of Lipocine worth $280,000 at the end of the most recent reporting period. 9.11% of the stock is owned by institutional investors and hedge funds.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.